About Embla Medical

Sveinn Sölvason, President and CEO, comments:

“Sales in Q2 2026 were USD 259 million, representing 11% reported growth and 6% organic growth. Strong double-digit Prosthetics & Neuro Orthotics growth in Q2, supported by excellent execution, robust volume growth in EMEA and APAC, and successful new product launches. Bracing & Supports delivered moderate growth in the quarter, while Patient Care declined.

The EBITDA margin was strong at 22% in Q2 2026, up 1%-point from Q2 2025, reflecting solid sales contribution from Prosthetics & Neuro Orthotics, continued cost discipline, and US tariff refunds."

Embla will host a conference call on April 28, 2026 at 09:00 CET / 7:00 GMT / 3:00 EST.

Please visit our Investor Relations section for further information

We serve our investors, by communicating in an informative and honest way. We are ambitious about the way we interact. It is our policy to provide investors, analysts and other stakeholders with comprehensive and accurate information to improve the understanding of the current and expected development of Embla Medical.